EGFR Pathway Expression Persists in Recurrent Glioblastoma Independent of Amplification Status.

ABSTRACT:

Background

Glioblastoma mortality is driven by tumour progression or recurrence despite administering a therapeutic arsenal consisting of surgical resection, radiation, and alkylating chemotherapy. The genetic changes underlying tumour progression and chemotherapy resistance are poorly understood.

Methods

In this study, we sought to define the relationship between EGFR amplification status, EGFR mRNA expression, and EGFR pathway activity. We compared RNA-sequencing data from matched primary and recurrent tumour samples (n = 40 patients, 20 with EGFR amplification).

Results

In the setting of glioblastoma recurrence, the EGFR pathway was overexpressed regardless of EGFR-amplification status, suggesting a common genomic endpoint in recurrent glioblastoma, although

SUBMITTER: Dhawan A 

PROVIDER: S-EPMC9913094 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature